Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
4.8
-45.54%
60%
—
60.97%
60%
—
5 Years
Score4.8
Net Growth-45.54%
Net Trend60%
Net Income Consistency—
Rev Growth60.97%
Rev Trend60%
Revenue Consistency—
Sutro Biopharma fundamental performance
Between 2020 and 2025, revenue grew from $ 42M to $ 102M and net income went from -$ 32M to -$ 191M. Revenue increased in 3 of those 5 years; net income in 3.
Sutro Biopharma currently holds a 5-year HDB Score of 4.8 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 21.30 | — |
1 Year2025-08-12 | $ 7.84 | 171.79% |
5 Years2021-08-12 | $ 185.60 | -88.52% |
All Time2018-09-27 | $ 152.00 | -85.99% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2018-09-27 |
|---|---|---|---|---|
| Price | $ 21.30 | $ 7.84 | $ 185.60 | $ 152.00 |
| Return | — | 171.79% | -88.52% | -85.99% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 99M | -$ 153M | $ 202M |
| 2025 | $ 102M | -$ 191M | $ 141M |
| 2024 | $ 62M | -$ 227M | $ 316M |
| 2023 | $ 153M | -$ 106M | $ 375M |
| 2022 | $ 67M | -$ 119M | $ 334M |
| 2021 | $ 61M | -$ 105M | $ 197M |
| 2020 | $ 42M | -$ 32M | $ 368M |
| 2019 | $ 42M | -$ 55M | $ 117M |
| IPO2018 | $ 38M | -$ 35M | $ 204M |
Explore beyond STRO
You're looking at Sutro Biopharma. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
